Literature DB >> 11522228

Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells.

Y J Kim1, H E Broxmeyer.   

Abstract

A fundamental problem of antitumor immunity is tumor-induced immunosuppression. Tumor cells often down-regulate expression of co-stimulatory molecules, tumor antigens, and major histocompatibility complex (MHC) molecules on tumor cells, secrete immunosuppressive substance such as transforming growth factor-beta (TGF-beta) or interleukin-4 (IL-4), and induce apoptosis of effector T cells to escape surveillance. A major goal of antitumor or antivirus immunotherapy is to generate long-lived protective T cells that enable killing of target cells. In this review, we discuss the importance of 4-1BB for development or survival of functionally active effector CD8(+) T cells against tumors, virus infection, and allogeneic immune responses and for potential therapeutic application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522228     DOI: 10.1089/15258160152509064

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  4 in total

1.  Tumor necrosis factor receptor subfamily 9 (Tnfrsf9) gene is expressed in distinct cell populations in mouse uterus and conceptus during implantation period of pregnancy.

Authors:  Kirsten Eckstrum; Brent M Bany
Journal:  Cell Tissue Res       Date:  2011-05-12       Impact factor: 5.249

2.  Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors.

Authors:  Sabrina Sapski; Nadine Beha; Roland Kontermann; Dafne Müller
Journal:  Oncoimmunology       Date:  2017-08-17       Impact factor: 8.110

Review 3.  Immunotherapy for melanoma: the good, the bad, and the future.

Authors:  Christian H Poehlein; Dominik Rüttinger; Jun Ma; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

4.  A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer.

Authors:  Marcia Meseck; Tiangui Huang; Ge Ma; George Wang; Shu-Hsia Chen; Savio L C Woo
Journal:  J Immunother       Date:  2011-03       Impact factor: 4.456

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.